A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 21 Jun 2025
At a glance
- Drugs AMG 193 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms MTAPESTRY 201
- Sponsors Amgen
Most Recent Events
- 20 Feb 2025 Planned End Date changed from 19 Feb 2029 to 11 Sep 2029.
- 20 Feb 2025 Planned primary completion date changed from 28 Feb 2025 to 12 Sep 2027.
- 09 Jan 2025 Status changed from not yet recruiting to recruiting.